Shots:
- Beam to receive $50M up front and $25M as near-term milestones & will be eligible to receive other milestones along with royalties on sales, following the exercise of the option. The companies will work on 6 research programs focusing on C3 & other complement targets in the eye, liver, and brain
- Apellis holds exclusive rights to license each of the 6 programs & responsible for subsequent development. Beam may elect to enter a 50-50 co-development & co-commercialization agreement with Apellis for one of the programs licensed under the collaboration
- Beam will utilize its base editing technology and conduct preclinical research on up to 6 base editing programs. The companies can extend the collaboration up to 2yrs. on a per year and program-by-program basis
Click here to read full press release/ article | Ref: Apellis | Image: Apellis
The post Apellis and Beam Sign a Five-Year Research Collaboration to Discover Novel Therapies for Complement-Driven Diseases first appeared on PharmaShots.
